Effect of Macitentan on Long-term Outcomes in Patients With Pulmonary Arterial Hypertension (PAH): Subanalysis of SERAPHIN Comparing Incident and Prevalent Patient Populations Not Treated With Background PAH-Specific Therapy

被引：0
|
作者：
Simonneau, Gerald
Channick, Richard
Delcroix, Marion
Galie, Nazzareno
Ghofrani, Hossein
Jansa, Pavel
Le Brun, Franck-Olivier
Mehta, Sanjay
Perchenet, Loic
Pulido, Tomas
Sastry, B.
Sitbon, Olivier
Souza, Rogerio
Torbicki, Adam
Rubin, Lewis
机构：
来源：
CHEST | 2013年 / 144卷 / 04期
关键词：
D O I：
10.1378/chest.1701395
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
876A
引用
收藏
页数：3
相关论文
共 50 条
  • [1] EFFECT OF MACITENTAN ON LONG-TERM OUTCOMES IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH): SUB-ANALYSIS OF SERAPHIN COMPARING INCIDENT AND PREVALENT PATIENT POPULATIONS NOT TREATED WITH PAH-SPECIFIC THERAPY AT BASELINE
    Williams, T.
    Galie, N.
    Perchenet, L.
    Rubin, L.
    Simonneau, G.
    RESPIROLOGY, 2014, 19 : 28 - 28
  • [2] Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy?
    Peter Steele
    Geoff Strange
    John Wlodarczyk
    Brad Dalton
    Simon Stewart
    Eli Gabbay
    Anne Keogh
    BMC Cardiovascular Disorders, 10
  • [3] Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy?
    Steele, Peter
    Strange, Geoff
    Wlodarczyk, John
    Dalton, Brad
    Stewart, Simon
    Gabbay, Eli
    Keogh, Anne
    BMC CARDIOVASCULAR DISORDERS, 2010, 10
  • [4] Anticoagulant therapy does not influence long-term outcomes in patients with pulmonary arterial hypertension (PAH): insights from the randomised controlled SERAPHIN trial of macitentan
    Galie, N.
    Delcroix, M.
    Ghofrani, H. -A.
    Jansa, P.
    Minai, O. A.
    Perchenet, L.
    Rubin, L. J.
    Sastry, B. K. S.
    Torbicki, A.
    Simonneau, G.
    EUROPEAN HEART JOURNAL, 2014, 35 : 10 - 10
  • [5] EFFICACY AND SAFETY OF LONG-TERM PAH-SPECIFIC MONO-THERAPY WITH BOSENTAN IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION
    Paramonov, V.
    Martynyuk, T.
    Chazova, I. E.
    JOURNAL OF HYPERTENSION, 2015, 33 : E195 - E195
  • [6] Long-term sitaxsentan therapy in Pulmonary Arterial Hypertension (PAH)
    Horn, E
    Langleben, D
    Frost, A
    Hill, N
    McLaughlin, V
    Oudiz, R
    Dixon, RAF
    Barst, RJ
    EUROPEAN HEART JOURNAL, 2004, 25 : 466 - 466
  • [7] REPAIR: LONG-TERM EFFECTS OF MACITENTAN ON THE RIGHT VENTRICLE (RV) IN PULMONARY ARTERIAL HYPERTENSION (PAH)
    Kiely, D. G.
    Cottreel, E.
    Galie, N.
    Tarcus, J. T.
    Peacock, A.
    Rosenkranz, S.
    Swift, A. J.
    Tawakol, A.
    Torbicki, A.
    Noordegraaf, A. Vonk
    Wetherill, G.
    Channick, R.
    THORAX, 2021, 76 : A56 - A57
  • [8] REPAIR: long-term effects of macitentan on the right ventricle (RV) in pulmonary arterial hypertension (PAH)
    Kiely, David
    Cottreel, Emmanuelle
    Galie, Nazzareno
    Marcus, J. Tim
    Peacock, Andrew
    Rosenkranz, Stephan
    Swift, Andrew J.
    Tawakol, Ahmed
    Torbicki, Adam
    Noordegraaf, Anton Vonk
    Wetherill, Graham
    Channick, Richard
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [9] Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH)
    Calcaianu, George
    Chaouat, Ari
    Canuet, Matthieu
    Kessler, Romain
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [10] Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH)
    Calcaianu, George
    Calcaianu, Mihaela
    Canuet, Matthieu
    Enache, Irina
    Kessler, Romain
    PULMONARY CIRCULATION, 2017, 7 (02) : 439 - 447
12345